Gavin Wood - Sep 2, 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)

Signature
/s/ Gavin Wood
Stock symbol
ADAP
Transactions as of
Sep 2, 2025
Transactions value $
-$950
Form type
4
Date filed
9/3/2025, 05:00 PM
Previous filing
Jan 17, 2024

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wood Gavin Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC,, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, UNITED KINGDOM /s/ Gavin Wood 2025-09-03 0001577539

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADAP Ordinary Shares with a nominal value of GBP0.001 per share Sale -$950 -96K -100% $0.01* 0 Sep 2, 2025 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.
F2 The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs.
F3 The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
F4 The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer.